Rigel Pharmaceuticals
RIGL
47.69
-0.31
-0.64%
Rigel Pharmaceuticals
US · RIGL
#3318 by market cap
47.69
-0.31
-0.64%
Live - 5344 symbols - heartbeat 321s ago
· 2026-10-08 09:53
After-hours
47.00
-2.06%
- Market cap
- 890.75M
- P/E (TTM)i
- 2.82
- P/Bi
- 2.09
- EPSi
- 19.48
- Div yieldi
- 0.00%
- 52W posi
- 83%
Reader sentiment
Are you bullish or bearish on RIGL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.3 percentage points.
Institutional ownership
- Held by institutions
- 90.89% -2.31pp
- Institutions
- 201 -4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund55.27%
Hedge Fund30.00%
Public Company3.03%
Individual/Insider1.74%
Government Pension Fund0.73%
Bank/Investment Bank0.62%
Family Office/Trust0.56%
Private Company0.36%
Insurance Company0.25%
Other7.44%
Top holders as of 2026-06-30
BlackRock
10.38% · 1.94M sh
Soleus Capital Management, L.P.
9.87% · 1.84M sh
Armistice Capital LLC
8.95% · 1.67M sh
State Street Global Advisors
5.57% · 1.04M sh
Vanguard Capital Management, LLC
4.85% · 906.84K sh
American Century Investment Management
3.97% · 741.72K sh
LSV Asset Management
3.86% · 721.67K sh
Acadian Asset Management LLC
3.17% · 591.69K sh
D. E. Shaw & Co., L.P.
2.90% · 542.54K sh
Geode Capital Management, LLC
2.59% · 483.18K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 22 sells
| Name | Role | Stake |
|---|---|---|
| Raul Rodriguez | Chief Executive Officer | 0.96% |
| Dean Schorno | Chief Financial Officer | 0.24% |
| David Santos | Executive Vice President | 0.12% |
| Raymond Furey | General Counsel | 0.08% |
| Walter Moos | Independent Director | 0.07% |
| Jane Wasman | Independent Director | 0.07% |
| Gregory Lapointe | Independent Chairperson | 0.07% |
| Alison Hannah | Independent Director | 0.06% |
| Kamil Jackson | Independent Director | 0.05% |
| Lisa Rojkjaer | Chief Medical Officer | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-01 | Dean Schorno | Chief Financial Officer | Derivative Exercise and Retained | +4,600 | $12.70–24.20 |
| 2026-08-31 | Raul Rodriguez | Chief Executive Officer | Sale to Issuer | -2,424 | $47.50 |
| 2026-08-31 | Dean Schorno | Chief Financial Officer | Sale to Issuer | -928 | $47.50 |
| 2026-08-31 | Raymond Furey | General Counsel | Sale to Issuer | -877 | $47.50 |
| 2026-08-31 | David Santos | Executive Vice President | Sale to Issuer | -874 | $47.50 |
| 2026-07-07 | Alison Hannah | Independent Director | Other Acquisition | +24,400 | -- |
| 2026-06-21 | Kamil Jackson | Independent Director | Automatic Disposition | -2,500 | $35.00 |
| 2026-06-16 | Raul Rodriguez | Chief Executive Officer | Other Derivative Acquisition | +31,700 | $22.49 |
| 2026-06-16 | Lisa Rojkjaer | Chief Medical Officer | Other Derivative Acquisition | +16,769 | $14.90–22.49 |
| 2026-06-16 | Dean Schorno | Chief Financial Officer | Other Derivative Acquisition | +7,394 | $22.49 |
| 2026-06-16 | Raymond Furey | General Counsel | Other Derivative Acquisition | +7,394 | $22.49 |
| 2026-06-16 | David Santos | Executive Vice President | Other Derivative Acquisition | +7,394 | $22.49 |
| 2026-05-31 | Raul Rodriguez | Chief Executive Officer | Sale to Issuer | -2,424 | $29.86 |
| 2026-05-31 | Lisa Rojkjaer | Chief Medical Officer | Sale to Issuer | -850 | $29.86 |
| 2026-05-31 | Dean Schorno | Chief Financial Officer | Derivative Exercise and Sale | -928 | $12.70–29.86 |
| 2026-05-31 | Dean Schorno | Chief Financial Officer | Derivative Exercise and Retained | +2,453 | $12.70–18.70 |
| 2026-05-31 | Raymond Furey | General Counsel | Sale to Issuer | -877 | $29.86 |
| 2026-05-31 | David Santos | Executive Vice President | Sale to Issuer | -874 | $29.86 |
| 2026-05-25 | Kamil Jackson | Independent Director | Automatic Disposition | -2,500 | $29.17 |
| 2026-05-14 | Walter Moos | Independent Director | Other Acquisition | +5,750 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:53:13 · For reference only, not investment advice and not tailored to your situation.